An observational study in Acute Respiratory Distress Syndrome, Sepsis and Hypoalbuminemia, sponsored by The Second Affiliated Hospital of Hainan Medical University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by The Second Affiliated Hospital of Hainan Medical University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 146 studies in Respiratory Distress Syndrome with a site in China — 54 open to participants now, 55 under way, 6 of them phase 3. Respiratory Distress Syndrome · China.
Among the 146 studies in Respiratory Distress Syndrome with a site in China, this one is the 28th largest by planned enrollment of the 65 observational ones that give a count, is one of 14 that started in 2026, is one of 65 observational ones, reaches primary completion later than 41 of the 54 other live ones, and was the 145th registered.
1,389 studies on the registry are indexed under Respiratory Distress Syndrome; 281 are open to participants now.
Browse Respiratory Distress Syndrome studies →54 of the 146 studies in Respiratory Distress Syndrome with a site in China are open now. Recruiting first, the newest first:
Southeast University, China · Sites in China
Ruijin Hospital · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Southeast University, China · Sites in China
Ages 18+
Bin Du · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 196 Respiratory Distress Syndrome studies recruiting now, 116 (59%) set no upper age limit and 50 (26%) stop at 75 or younger; 52 take children under 18; 9 take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
146 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 16 · Phase 3 7 · Phase 4 5
First in 2006; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 260 is above the median of 100 across 476 observational studies indexed under Respiratory Distress Syndrome.
Median enrollment 100 across the 81 interventional studies, 139 across the 65 observational. Of the 52 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 146 have an industry lead sponsor. The 10 most frequent:
The Second Affiliated Hospital of Hainan Medical University is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
The Second Affiliated Hospital of Hainan Medical University has 1 study filed under Respiratory Distress Syndrome — fewer than ten, so there is no comparison to draw.
17 of the studies in Respiratory Distress Syndrome with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07342205Phase 3Shanghai University of Traditional Chinese MedicineA Study on the Treatment of Patients With Acute Lung Injury Caused by Sepsis Through Microbiota Transplantation | 2027-06 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT07798154Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyEffect of Spontaneous Breathing in APRV Mode on Respiratory Physiology of ARDS Patients | 2026-11 |
| NCT07413094Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS | 2026-12 |
| NCT06430554Zhongda HospitalPersonalized Ventilation Based on Ventilation-perfusion Mismatch and Lung Recruitability | 2026-12-30 |
Add all 17 to your calendar (.ics) → With an account.
Among the 146 studies in Respiratory Distress Syndrome with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Sepsis-associated acute respiratory distress syndrome (ARDS) is a severe condition where severe infection causes fluid accumulation in the lungs, often requiring invasive mechanical ventilation. Patients with low blood albumin levels are particularly vulnerable to this fluid leakage, leading to prolonged dependence on a ventilator.
This observational study evaluates the association between a targeted human albumin treatment strategy combined with clinically guided fluid removal, and clinical outcomes in adults with sepsis-associated ARDS and low blood albumin levels (≤ 30 g/L).
Conducted at a single hospital, this study compares two groups. The prospective group consists of patients receiving current usual clinical care, where albumin administration and fluid management are determined by the treating clinical team. Their outcomes will be compared to a historical control group of similar patients who received standard care before this targeted albumin management strategy was routinely implemented.
The primary objective is to evaluate whether this targeted albumin strategy is associated with an increase in Ventilator-Free Days at day 28 (VFD-28). VFD-28 reflects both patient survival and successful liberation from the ventilator. The study will also observe secondary outcomes including oxygenation improvement, fluid balance, organ function, mortality, and safety events (e.g., fluid overload or allergic reactions). As an observational study, researchers do not assign treatments; all interventions are based on real-world clinical judgment.
Background and Rationale Hypoalbuminemia is common in patients with sepsis-associated ARDS and alters colloid osmotic pressure, exacerbating pulmonary edema and prolonging mechanical ventilation. While human albumin administration during the de-resuscitation phase may support intravascular volume and facilitate fluid removal (via diuretics or CRRT), real-world evidence evaluating a structured, targeted albumin strategy specifically in this vulnerable subpopulation remains limited.
Study Design and Cohorts This is a single-center, prospective observational study with a historical control cohort. The study employs a before-and-after design to evaluate real-world clinical outcomes.
Historical Control Cohort: Eligible patients identified retrospectively who received usual clinical care (primarily crystalloid-based fluid management) prior to the routine implementation of the targeted albumin strategy. Any occasional albumin use in this cohort will be documented and adjusted for in statistical analyses.
Prospective Observational Cohort: Eligible patients receiving current standard of care, which includes human albumin administration (aiming for serum albumin ≥ 30 g/L) and fluid de-resuscitation. Treatment decisions, including albumin dose, frequency, and fluid targets, remain entirely under the discretion of the treating clinical team.
Time Origin (Time Zero, T0) Definition To strictly prevent immortal time bias, the study time origin (T0) is defined as the exact timestamp when a patient simultaneously fulfills all required eligibility conditions: (1) Sepsis-3 criteria met, (2) ARDS criteria met, (3) invasive mechanical ventilation active, and (4) confirmed serum albumin ≤ 30 g/L. All baseline covariates, propensity score matching variables, and outcome observation windows strictly anchor to T0. If mechanical ventilation begins before T0, the actual ventilation start time is retained for the ventilation history but outcome computation (e.g., VFD-28) strictly starts at T0.
Exposure Definition (Observational Context) The primary exposure is management with a targeted human albumin strategy combined with fluid de-resuscitation. As an observational study, the protocol does not mandate therapy. Instead, it observes and records treatments delivered in routine clinical care. Data on albumin concentration, cumulative dose, fluid intake/output, diuretic use, and CRRT net ultrafiltration are prospectively collected.
Outcome Assessment and Statistical Analysis The primary outcome is Ventilator-Free Days at day 28 (VFD-28), calculated from T0. Patients who die within 28 days are assigned zero VFDs.
To mitigate confounding by indication and calendar time bias, a 1:1 Propensity Score Matching (PSM) will be utilized. Covariates (e.g., age, APACHE II, baseline SOFA, PaO2/FiO2, lactate, and cumulative fluid balance) are strictly restricted to pre-T0 values to avoid overadjustment by post-treatment mediators.
The primary outcome (VFD-28) will be analyzed evaluating the absolute difference between matched groups. As a key secondary analysis, a Fine-Gray competing-risk model will be used to evaluate the cumulative incidence of successful liberation from ventilation, treating death as a competing event. Repeated measures (e.g., albumin levels, oxygenation) will be evaluated using generalized estimating equations (GEE) or linear mixed-effects models (LMM).
The study population comprises critically ill adult patients admitted to the intensive care units (ICUs) at the Second Affiliated Hospital of Hainan Medical University. Eligible participants are those diagnosed with sepsis-associated acute respiratory distress syndrome (ARDS) who require invasive mechanical ventilation and have confirmed hypoalbuminemia (serum albumin ≤ 30 g/L). The prospective cohort is identified consecutively from active ICU admissions, while the historical control cohort is identified retrospectively from electronic medical records of patients admitted prior to the routine implementation of the targeted albumin protocol.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients enrolled prospectively receiving current usual clinical care, which includes a targeted human albumin treatment strategy (aiming to maintain serum albumin ≥ 30 g/L) combined with protocolized fluid de-resuscitation. Treatment decisions remain entirely under the discretion of the treating clinical team.
Patients identified retrospectively from electronic medical records who received usual clinical care (primarily crystalloid-based fluid management without a targeted albumin protocol) prior to the routine implementation of the targeted albumin strategy.
Ventilator-Free Days at Day 28 (VFD-28)
VFD-28 is defined as the number of days from Time Zero (T0) to day 28 that a patient is alive and successfully liberated from invasive mechanical ventilation (defined as being free from the ventilator for at least 48 consecutive hours). Patients who die within the 28-day observation period are assigned zero VFDs, regardless of their ventilation status prior to death.
Time frame: Up to 28 days from Time Zero (T0)
Cumulative Incidence of Successful Liberation from Ventilation
Analyzed using a competing-risk model (treating death as a competing event) to evaluate the probability of successful weaning from invasive mechanical ventilation.
Time frame: Up to 28 days from Time Zero (T0)
Cumulative Fluid Balance
The daily net fluid balance evaluated to reflect the de-resuscitation trajectory. It is calculated by subtracting total fluid output (including net ultrafiltration from CRRT, if applicable) from total fluid intake.
Time frame: From Day 1 to Day 7
Change in Oxygenation Index (PaO2/FiO2 Ratio)
The daily worst PaO2/FiO2 ratio measured to evaluate the trajectory of lung function and pulmonary edema resolution.
Time frame: From Day 1 to Day 7
28-Day All-Cause Mortality
The proportion of patients who die from any cause within the 28-day observation period.
Time frame: At Day 28
Plan to share: No
Start is estimated for Nov 2026; primary completion for Oct 2027, 10 months later.
Of 228 non-industry observational studies under Respiratory Distress Syndrome, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 10 months is below that.
Counting every sponsor, half of 234 studies reached it within 24 months; a quarter within 12 and three quarters within 49.
Start moved once since we started tracking on Sep 25, 2026: Oct 2026 → Nov 2026, on Nov 17, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Respiratory Distress Syndrome →
The Second Affiliated Hospital of Hainan Medical University